ACTH (Acthar Gel)

Drug Overview

In the specialized field of Neurology, rapidly halting severe pediatric seizures is vital to protect a child’s developing brain. ACTH (Acthar Gel) is a cornerstone medication belonging to the Melanocortin Receptor Agonists drug class. It is primarily utilized as a highly potent Steroid Therapy to treat infantile spasms, a rare and catastrophic form of childhood epilepsy.

Classified as a naturally derived Biologic, Acthar Gel goes beyond standard synthetic steroids. It functions as a specialized Immunotherapy and Targeted Therapy that harnesses the body’s own endocrine system. By stimulating the adrenal glands and acting directly on the brain’s receptors, it effectively quiets the chaotic electrical activity (hypsarrhythmia) that causes spasms, offering a critical alternative to traditional low-dose corticosteroid treatments.

• Generic Name: Adrenocorticotropic hormone (Repository corticotropin injection)
  
• US Brand Names: H.P. Acthar Gel
  
• Route of Administration: Intramuscular (IM) Injection
  
• FDA Approval Status: Fully FDA-approved as a monotherapy for the treatment of infantile spasms in infants and children under 2 years of age, as well as for various systemic autoimmune and inflammatory conditions.
  

What Is It and How Does It Work? (Mechanism of Action)

ACTH is a highly purified preparation of adrenocorticotropic hormone extracted from porcine (pig) pituitary glands. In the context of infantile spasms, the exact disease process is believed to involve an overproduction of Corticotropin-Releasing Hormone (CRH) in the infant’s brain, which acts as a powerful seizure-triggering chemical.

At the molecular level, this Biologic utilizes a dual mechanism of action:

• Adrenal Steroidogenesis (Systemic Effect): ACTH travels through the bloodstream and binds specifically to Melanocortin-2 Receptors (MC2R) on the surface of the adrenal cortex. This binding activates the adenylate cyclase/cAMP signaling pathway, forcing the adrenal glands to produce and release a massive surge of endogenous (natural) glucocorticoids, mineralocorticoids, and androgens. These natural steroids aggressively suppress systemic and neurological inflammation.
  
• Direct Neuro-Modulation (Central Effect): Unlike standard steroid pills, ACTH crosses the blood-brain barrier and binds directly to other melanocortin receptors (MC1R, MC3R, MC4R) located in the central nervous system. This direct binding acts as a Targeted Therapy that downregulates the brain’s release of the excitatory, seizure-causing CRH. By lowering CRH levels and modulating nerve excitability, ACTH physically stabilizes the brain’s electrical environment to stop the spasms.
  

FDA-Approved Clinical Indications

Primary Indication

• Infantile Spasms (West Syndrome): Specifically indicated to induce a complete cessation of clinical spasms and resolve the chaotic brain wave patterns (hypsarrhythmia) in infants and children under 2 years old.
  

Other Approved Uses

Acthar Gel’s potent anti-inflammatory properties make it FDA-approved for severe exacerbations of multiple conditions:

• Neurology: Acute exacerbations of Multiple Sclerosis (MS) in adults.
  
• Nephrology: Inducing diuresis or remission of proteinuria in Nephrotic Syndrome.
  
• Rheumatology: Acute flares of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
  
• Ophthalmology: Severe acute and chronic allergic and inflammatory processes involving the eye (e.g., optic neuritis, keratitis).
  
• Dermatology: Severe erythema multiforme (Stevens-Johnson syndrome) and systemic lupus erythematosus.
  

Dosage and Administration Protocols

Treating infantile spasms with ACTH requires high doses to rapidly stop the seizures, followed by a meticulous tapering schedule to allow the infant’s natural adrenal glands to resume normal function. Dosage is calculated based on the infant’s Body Surface Area (BSA).

Clinical Protocol Notes

• Tapering Requirement: The medication must never be stopped abruptly. Sudden discontinuation can cause a life-threatening adrenal crisis because the body’s natural steroid production has been temporarily “put to sleep.”
  
• Renal/Hepatic Insufficiency: No strict dose adjustments are universally required for liver or kidney impairment, but infants must be monitored closely for severe fluid retention and electrolyte imbalances.
  
• Injection Site: Injections are typically given into the large thigh muscle (anterolateral aspect).
  

Clinical Efficacy and Research Results

Current clinical data and retrospective neurological registries (2020-2026) validate ACTH as a highly effective, first-line intervention for infantile spasms:

• Spasm Cessation: Standardized clinical trials demonstrate that high-dose ACTH therapy completely stops clinical spasms in approximately 70% to 85% of infants, often within the first 7 to 14 days of treatment.
  
• EEG Normalization: ACTH is highly successful at resolving hypsarrhythmia on an EEG, which is a critical marker for a true clinical response and long-term brain health.
  
• Developmental Preservation: Recent longitudinal studies show that infants who achieve rapid spasm cessation with ACTH have significantly better cognitive and motor development scores at age 3 compared to those whose spasms remain uncontrolled, highlighting the importance of early and aggressive intervention.
  

Safety Profile and Side Effects

While ACTH does not currently carry a “Black Box Warning,” it possesses a severe side effect profile identical to that of extreme high-dose corticosteroids.

Common Side Effects (>10%)

• Increased Appetite and Weight Gain: Rapid weight gain and fluid retention are universally expected.
  
• Cushingoid Appearance: Rounding of the face (“moon face”) and redistribution of body fat.
  
• Irritability: Extreme fussiness, poor sleep, and crying (often referred to as “steroid rage” in infants).
  
• Hypertension: Elevated blood pressure requiring routine monitoring.
  

Serious Adverse Events

• Immunosuppression and Infection: ACTH profoundly suppresses the immune system. Because it also reduces inflammation, it can “mask” the signs of a severe, life-threatening infection (e.g., an infant may have pneumonia or sepsis without ever developing a fever).
  
• Adrenal Insufficiency: If the taper is too fast or the drug is stopped suddenly, the infant can go into shock.
  
• Cardiac Hypertrophy: Reversible thickening of the heart walls can occur during high-dose therapy.
  
• Gastrointestinal: Risk of gastric ulcers or intestinal bleeding.
  

Management Strategies

• Blood Pressure and Cardiac Monitoring: Weekly blood pressure checks and baseline/follow-up echocardiograms are often recommended.
  
• Infection Vigilance: Parents must treat any minor change in behavior, breathing, or feeding as a potential medical emergency, even if the child does not feel warm to the touch.
  

Research Areas

In the rapidly evolving fields of Regenerative Medicine and developmental neurobiology, melanocortin receptor agonists like ACTH are drawing interest for their profound neuroprotective properties. Current research (2025-2026) is investigating how reducing brain-wide neuroinflammation and clearing toxic excitatory chemicals (like CRH) creates a “permissive microenvironment” for brain healing. While ACTH is not currently used directly alongside cellular therapy, establishing this non-inflammatory baseline is viewed as a vital theoretical step for ensuring the survival and successful integration of future Stem Cell therapies aimed at repairing epileptic brain damage in children.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Baseline EEG: To confirm the diagnosis of infantile spasms and hypsarrhythmia.
  
• Baseline Vitals: Heart rate, blood pressure, and a baseline echocardiogram to monitor for cardiac changes.
  
• Comprehensive Blood Panel: To check baseline electrolytes (specifically potassium and sodium) and screen for any hidden infections before suppressing the immune system.
  

Precautions During Treatment

• Avoid Live Vaccines: The infant must absolutely not receive any live or live-attenuated vaccines (such as MMR, Rotavirus, or Varicella) during treatment and for a period afterward, as their immune system cannot safely process them.
  
• Exposure Reduction: Limit the infant’s exposure to crowds, daycares, or anyone who is sick.
  

“Do’s and Don’ts” List

• DO rotate the injection sites between the left and right thigh every single time to prevent muscle damage or dimpling.
  
• DO wash your hands meticulously before preparing the injection and before handling the infant.
  
• DON’T stop the medication abruptly or alter the tapering schedule without explicit instructions from your neurologist.
  
• DON’T ignore a “feverless” illness. If your child becomes unusually lethargic, stops eating, or breathes rapidly, seek emergency medical care immediately, as it could be a masked infection.
  

Legal Disclaimer

This guide is intended for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Infantile spasms represent a medical emergency, and the use of Acthar Gel requires precise medication management and strict ongoing supervision by a board-certified pediatric neurologist. Always consult your healthcare provider before initiating, altering, or stopping any medication regimen.